Loading
A phase 1/2 trial of AK127 in combination with AK112 in advanced solid tumours, run by Akeso, active and no longer recruiting.
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05951608 by Akeso, with 216 participants enrolled, started 2023-10-16 and due to reach its primary completion in 2026-05-01. Interventions recorded: AK127 in combination with AK112.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/